Small Molecules Capability
Australia is ideally positioned to be a major player in the global Pharma ecosystem where risk-averse companies are looking to in-licence assets that have demonstrated development potential.
Therefore, to enhance the progression of early stage discoveries through to preclinical development, TIA has formed a Small Molecules capability which is an integrated capability network of National Research Infrastructure across Australia. These facilities are committed to provide high quality research infrastructure to support leading‑edge research and to boost innovation in Australia.
